Greg Harrison
Stock Analyst at Scotiabank
(4.02)
# 535
Out of 4,960 analysts
99
Total ratings
57.89%
Success rate
9.99%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $17.92 | +72.99% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $12.30 | +62.60% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $49.08 | +16.14% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $395.12 | +10.85% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $454.38 | -0.96% | 6 | Aug 1, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $71 → $65 | $38.80 | +67.53% | 7 | Jul 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.64 | +9.89% | 8 | Jul 25, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $2.34 | +370.09% | 1 | Jul 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Sector Outperform | $32 → $35 | $18.51 | +89.09% | 2 | Jul 2, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $321 → $315 | $312.23 | +0.89% | 4 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $22.57 | +143.69% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $26.84 | +37.85% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $15.56 | +67.10% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $27.97 | -28.49% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.46 | +2.74% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $16.64 | +140.38% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $60.35 | +24.28% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $11.83 | +52.16% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $10.52 | +765.02% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $19.56 | -38.65% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.59 | +155.84% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $14.89 | +162.01% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.80 | +435.71% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $4.40 | -31.82% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.65 | +4,155.32% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $16.96 | +218.40% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $27.03 | +232.96% | 5 | Mar 14, 2022 |
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $17.92
Upside: +72.99%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $12.30
Upside: +62.60%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $49.08
Upside: +16.14%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $395.12
Upside: +10.85%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $454.38
Upside: -0.96%
Agios Pharmaceuticals
Jul 28, 2025
Maintains: Sector Outperform
Price Target: $71 → $65
Current: $38.80
Upside: +67.53%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.64
Upside: +9.89%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $2.34
Upside: +370.09%
Arcturus Therapeutics Holdings
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $18.51
Upside: +89.09%
United Therapeutics
Jun 11, 2025
Maintains: Neutral
Price Target: $321 → $315
Current: $312.23
Upside: +0.89%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $22.57
Upside: +143.69%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $26.84
Upside: +37.85%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $15.56
Upside: +67.10%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $27.97
Upside: -28.49%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.46
Upside: +2.74%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $16.64
Upside: +140.38%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $60.35
Upside: +24.28%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $11.83
Upside: +52.16%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $10.52
Upside: +765.02%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $19.56
Upside: -38.65%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.59
Upside: +155.84%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $14.89
Upside: +162.01%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.80
Upside: +435.71%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $4.40
Upside: -31.82%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.65
Upside: +4,155.32%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $16.96
Upside: +218.40%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $27.03
Upside: +232.96%